A1M Pharma
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Scheelevägen 22, Lund, Skane, 223 63, Sw...Phone Number
+46 462865030Website
www.a1m.seRevenue
$5.7 MillionIndustry
ZI Rank: 1
About A1M Pharma
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is A1M Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at A1M Pharma
Check out if A1M Pharma is spiking on competitors!
Click to see if A1M Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on A1M Pharma recently announced quarterly report
Product Launch: Get notified when A1M Pharma launches new products
A1M Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once A1M Pharma has new funding data
Check if A1M Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding A1M Pharma
A1M Pharma's investigational drug ROSgard - based on the endogenous protein alpha-1-microglobulin - has in several non-clinical studies been documented to reduce acute kidney injury caused by oxidative stress by protecting exposed tissue and supporting regenerative processes. A1M Pharma is listed on Nasdaq First North Growth Market Stockholm. The c... Read More
